{
  "trial_id": "NCT00729157",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Histopathologically confirmed differentiated thyroid carcinoma of follicular cell origin",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "Papillary thyroid cancer dx w/ right neck mass",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "Metastatic to lymph nodes and adrenal glands",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "At least one fludeoxyglucose F 18 (FDG)-PET-avid lesion",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "Measurable disease, defined as \u2265 1 unidimensionally measurable lesion \u2265 20 mm by conventional techniques or \u2265 10 mm by spiral CT scan",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "Progressive disease, defined by \u2265 1 of the following occurring during or after prior treatment (e.g., radioactive isotope [RAI] treatment): Presence of new or progressive lesions on CT scan or MRI",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "No known history of brain metastasis",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "ANC \u2265 1,500/mcL",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "Platelet count \u2265 75,000/mcL",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "WBC \u2265 3,000/mcL",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "Total bilirubin \u2264 1.5 times upper limit of normal(ULN)",
      "label": "met",
      "evidence": "patient text"
    }
  ],
  "exclusion": [
    {
      "criterion": "No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "No history of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in the study",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has metastatic papillary thyroid cancer with progressive disease and meets most inclusion criteria. However, patient's history of high bleed risk due to proximity to trachea and recurrent laryngeal nerve may be a concern for eligibility.",
  "_meta": {
    "topic_id": "11",
    "trial_id": "NCT00729157",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}